Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2
about
Thunder and lightning: immunotherapy and oncolytic viruses collideIntelligent design: combination therapy with oncolytic virusesClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityOncolytic viruses as anticancer vaccinesCurrent issues and future directions of oncolytic adenoviruses.Impact of tumor microenvironment on oncolytic viral therapyCombination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing miceActivation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesAdenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse modelsCytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsAdoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escapePolymeric oncolytic adenovirus for cancer gene therapy.T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Pharmacologic and chemical adjuvants in tumor virotherapy.Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?The evolving role of dendritic cells in cancer therapy.Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma modelNew perspectives in cancer virotherapy: bringing the immune system into play.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Oncolytic virotherapyOncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Oncolytic Immunotherapy for Treatment of Cancer.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Systemic virotherapy for multiple myeloma.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide
P2860
Q24597894-5E8C35CD-1923-48C2-B349-3B86F70F03A2Q24628227-12B3B558-A413-4483-8C13-5C9F5DBA94AEQ26750568-2662B593-A9CE-46AD-815E-F8EEDBA8034FQ27025600-D9A99916-8A13-49AC-8D5F-DBAA4598E41BQ33730705-0EDB31F7-E9B7-4A4D-9071-1A070CD7BC26Q33895533-07522A6F-0EA2-4CC7-A4B1-F473C48CA5F1Q33927165-5C3F4818-3B46-4968-BE6B-11EBB0C179F1Q34059205-B3EAFAEA-6C08-40EA-8D0B-441AC92ADCFFQ34763999-228F114D-D101-429D-B381-AFC43E822B0AQ34988018-85023B22-8FDC-4ED4-ABDB-735C07C48DD1Q35596563-49C32CA2-7B4E-4B61-9E67-F01A2E330508Q35687743-6966DFD2-6765-4B58-9B91-876386634016Q36321054-F00EFB1E-0931-4CF5-93FB-45282724360CQ36344901-FCA7FB79-55B4-4843-9AE2-0B6BD87047B6Q36552580-5B4B3CB3-FB7D-4834-9CE3-778E08FC122BQ36574519-AFE2B9AE-6FF5-402C-83A6-6ED353E9A574Q36582819-9FF99DE1-639C-40DC-BF0B-77DC5D1D4EA9Q36890816-86AF97E9-9E26-4D2A-81AE-D0B0B2D936FEQ37459636-E646A4C0-68A2-43D3-A7B5-D2E03354767CQ37492540-906A03E2-E3FC-408D-B943-200FF8500EBFQ37513298-F83A7CEF-3470-4058-9CE0-2C8E51ECB5D3Q37687418-15EE82D8-FB1A-4F45-B9EA-C736FDFBD141Q37727843-B26D33C3-A764-4DEC-8EB6-60F76943A435Q37773253-8DB78628-0178-4E08-864A-DDB0F04C39C0Q37899223-6F7F09F3-9E17-4228-8658-A2E38FD660EBQ38008023-61EF4840-F513-4965-AC18-9329F7BFE657Q38025263-0D6A636F-AEC8-43D7-9F79-CBC6B2945280Q38058884-63E67E92-568B-477A-8905-1E4C5D63BA59Q38094806-7CCBF5F7-AEDB-47C2-979F-38124BBAC52CQ38218674-CF5CEB2A-3D1D-476B-8395-E2E92F43DC7FQ38223419-9C017319-267E-4C3F-A8AD-D7AE12AEA5C3Q38237657-91F4236D-56D7-4A3F-91A3-B50C4B61012CQ38848223-5DEF649C-0F2A-4991-84AC-6C963BF3695CQ39387174-15076F7E-691E-400E-A74B-59A790509167Q40087770-4DF183EC-1E18-408F-BAD2-8D3CC37735F4Q42157100-380D4B27-5B01-428F-A810-F86DECAE9E13
P2860
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Improved systemic delivery of ...... g modulation and interleukin-2
@ast
Improved systemic delivery of ...... g modulation and interleukin-2
@en
Improved systemic delivery of ...... g modulation and interleukin-2
@en-gb
Improved systemic delivery of ...... g modulation and interleukin-2
@nl
type
label
Improved systemic delivery of ...... g modulation and interleukin-2
@ast
Improved systemic delivery of ...... g modulation and interleukin-2
@en
Improved systemic delivery of ...... g modulation and interleukin-2
@en-gb
Improved systemic delivery of ...... g modulation and interleukin-2
@nl
prefLabel
Improved systemic delivery of ...... g modulation and interleukin-2
@ast
Improved systemic delivery of ...... g modulation and interleukin-2
@en
Improved systemic delivery of ...... g modulation and interleukin-2
@en-gb
Improved systemic delivery of ...... g modulation and interleukin-2
@nl
P2093
P2860
P50
P921
P1476
Improved systemic delivery of ...... g modulation and interleukin-2
@en
P2093
Jill Thompson
Jose Pulido
Kevin Harrington
Matt Coffey
Richard G Vile
Rosa Maria Diaz
Timothy Kottke
P2860
P356
10.1158/1078-0432.CCR-08-1688
P407
P577
2009-01-15T00:00:00Z